Cancer pain management in China: current status and practice implications based on the ACHEON survey

Zhongjun Xia
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Purpose: Cancer pain can seriously impact the quality of life (QoL) of patients, and optimal management practices are therefore of paramount importance. The ACHEON survey queried physicians and patients from 10 Asian countries/regions to assess current clinical practices in cancer pain management in Asia. This study presents the data obtained for cancer pain management in mainland China, with an emphasis on practices related to opioid drugs.

Materials and methods: In several tertiary hospitals across China, 250 patients experiencing cancer pain and 100 physicians were surveyed on questions designed to assess current cancer pain management practices and cancer pain impact on QoL.

Results: The patient survey showed that 88% of patients reported moderate-to-severe cancer pain, with a median duration of 6 months. The physician survey showed that medical school/residency training with regard to cancer pain management was inadequate in ~80% of physicians. A total of 80% of physicians and 67.2% of patients reported that pain scale was used during pain assessment; 84% of physicians expressed that physician-perceived pain severity was not completely consistent with actual pain the patient experienced. Of the 147 patients who recalled the medication received, 83.7% were administered opioid prescriptions. Of the 240 patients who received treatment, 43.8% perceived the inadequacy of controlling pain. The primary barriers from physicians perceived to optimal pain management included patients’ fear of side effects (58%), patients’ fear of addiction (53%), patients’ reluctance to report pain (43%), physicians’ reluctance to prescribe (29%), physicians’ inadequacy of pain assessment (27%) and excessive regulation of opioid analgesics (47%).

Conclusion: Knowledge of cancer pain management should be strengthened among physicians. Quantitative pain assessment and principle-based pain management should be combined to achieve pain relief. Misconceptions about opioids in patients and physicians and poor report about pain should be overcome through training/education to improve QoL of patients impacted by pain.

Keywords: cancer pain, pain management, opioid drugs, questionnaires

Introduction

More than 10 million people are diagnosed with cancer worldwide every year, with this number set to increase to >15 million by 2020. A significant number of cancer patients worldwide will experience pain during the course of their disease. A total of 70%–80% of patients with cancers in progressive stages have been reported to suffer from moderate-to-severe pain. Untreated or undertreated pain intensity and duration significantly impair the quality of life (QoL). A survey in a comprehensive hospital of China that interviewed 427 physicians and 387 cancer pain patients reported inadequate pain assessment and analgesia for cancer pain. Another survey in 30 hospitals in...
Beijing, China, reported that pain was completely relieved in merely 9.48% of 589 cancer patients. Improving the outcome of cancer pain management in patients has become a challenge for Chinese medical professionals. The barriers to optimize the management of cancer pain frequently cited by professionals and patients included knowledge deficits, inadequate pain assessment and misconceptions regarding pain. When opioid drugs were involved, restrictive regulation of controlled substances, concern about addiction, tolerance and side effects were mentioned by both physicians and patients. Other factors included high costs (non-reimbursable expenses) and non-availability of treatment. It is well known that opioid administration has been the primary therapeutic method for the management of moderate-to-severe cancer pain. Jacobson et al stated that the undertreatment of cancer pain could be caused by the barriers to the use of opioid analgesics. Caraceni et al reported evidence-based recommendations indicating that the skilled use of opioid analgesics is crucial to the relief of cancer pain. It must be noted that any approach of treating cancer pain might be impaired by numerous obstacles, such as access to medications and technologies and other factors that varied considerably from one country to another. Thus, it is essential to shed light on the current status of cancer pain management and guidance to improve therapeutic practices for the Chinese population.

The cross-sectional ACHEON survey, Current Practices of Cancer and Chronic Non-Cancer Pain Management: a pan-Asian study, represented the largest survey ever conducted on cancer pain management practices in Asia. This Asian survey received responses from 460 physicians in cancer-related fields and 1180 cancer patients from 10 Asian countries/regions, assessing clinical practices in cancer pain management (including mainland China, South Korea, Malaysia, Singapore, Philippines, Vietnam, Indonesia, Thailand, Hong Kong and Taiwan). The present study focused on the questionnaire data from 100 physicians and 250 patients surveyed in mainland China. To analyze the status about screening, assessment and treatment of cancer pain and to obtain physicians’ and patients’ perspectives with regard to cancer pain management, especially referring to opioid analgesics, we aimed at optimizing the outcome of cancer pain management.

**Materials and methods**

**Setting, sample and procedures**

Sampling was stratified by geographic region. Tertiary hospitals were selected from representative regions, including Shanghai (Eastern China), Beijing (Northern China), Guangzhou (Southeastern), Shenyang (Northeastern), Xi’an (Northwestern), Chengdu (Southwestern) and Wuhan (Central China). A total of 100 physicians and 250 patients were selected from both oncology and pain departments. Recruitment methods used for patients included patient referral, doctor referral, hospital intercept, door-to-door recruitment or patient associations. Patients (>18 years of age) who had experienced cancer pain for more than a month on admission were recruited with all cases pathologically confirmed. Patients experiencing pain that may have been caused by other reasons, those who had participated in other pain studies or those who were employees of pharmaceutical companies were excluded. Pain severity was evaluated by an 11-point Box Scale (BS-11) pain score of 0–10, where 0 is no pain at all and 10 is the worst pain imaginable. Mild pain, moderate pain and severe pain were defined as 0–3, 4–6 and 7–10 of BS-11 pain score, respectively. Physicians were randomly selected from databases of medical associations, official societies and national registries. All physicians included in the survey were required to have had at least 1 year of experience in the diagnosis and treatment of cancer pain.

The survey was conducted over 4 months (September 2013–December 2013) and carried out in accordance with the European Society for Opinion and Market Research (ESOMAR) code. No ethical approval was needed according to the Ethical Review of Biomedical Research Involving Human Beings (version 7 issued by National Health and Family Planning Commission of China). All physicians and patients involved in the survey have had their anonymity maintained and signed confidentiality agreements. All participants provided written informed consent before completing the survey questionnaire. Participation in the survey was voluntary, and investigators complied with both national and international laws while seeking to respect the rights and interests of the subjects surveyed.

**Survey questionnaire**

The ACHEON Physicians/Patient Questionnaire “Cancer Pain V1.0” (created by a steering committee consisting of 16 pain management experts) was used in the local language of the respective countries. Patients were administered the paper version or online version of the questionnaires to complete the quantitative 20-minute in-home interviews or at a location convenient to them. Physicians were scheduled for quantitative 20-minute interviews via telephone or face-to-face meetings at the physician’s office.

The physicians’ questionnaire data included 56 items about demographics (age, gender, profession, years of employment and training), pain assessment, pain management and attitudes (with regard to pain, pain assessment and pain management).
Data collection and data analyses
The paper and electronic surveys were exported into Microsoft Excel sheets. A series of numerical rating scale (NRS, 0–10 points) was used to assess attitudes toward cancer pain and clinical practice (pain screening, pain assessment and pain management with an emphasis on opioid analgesics). Here, NRS was just a 10-point scale. When the question was responded, NRS > 5 denotes a response indicating adequacy or agreement, NRS = 5 denotes a neutral response and NRS < 5 denotes inadequacy or disagreement. The results of the surveyed questions were expressed as a percentage of NRS > 5, the median NRS and the interquartile range (IQR) of NRS. The possible answers in the questionnaires were either yes or no or a 5-point scale from totally agree to totally disagree. The analysis included descriptive summaries of categorical variables that are given as frequencies and percentage. The analysis included continuous variables of non-normal distribution that are presented as median and IQR.

Results
General data of physicians and patients
Flowchart of the survey design is shown in detail in Figure 1, showing that 100 physicians and 250 patients surveyed completed the questionnaires in mainland China, with a response rate of 16.1% and 25.9%.
Survey respondents’ demographics of physicians are presented in detail in Table 1; 98% of physicians were medical/hematological oncologists.
Survey respondents’ demographics of patients are presented in detail in Table 2. Moderate-to-severe pain was reported in 88% of patients. The pain duration that exceeded 6 months was reported in 49.2% of patients.

Perceptions of physicians on cancer pain management
Perceptions of physicians could be acquired from Table 3. When queried about the education/training with regard to cancer pain management, only 28% and 17% of physicians believed that their medical school and residency training was adequate. As for prescribing opioids for treating cancer pain, only 22% and 20% of physicians believed that their medical school and residency training was adequate; 38% of physicians received pain-related continuing medical education (CME) per year of <10 hours.
The majority of physicians considered it important to follow guidelines to manage cancer pain. National guideline was

Figure 1 Flowchart of survey design, recruitment and selection phase of physicians and patients.
the top priority in 53% of physicians, followed by international guideline in 40% of physicians and hospital/practice-specific guideline in 7% of physicians. The concrete guidelines they adhered to are displayed in detail in Table 3.

In addition, 73% of physicians expressed that all patients were screened for pain on first and subsequent visits; 80% of physicians stated that they routinely assessed to quantify pain using pain scale for patients who present with pain. Besides BS-11 pain scale, physicians perceived that the pain assessment tools, shown in Figure S1A, can be used for patients who were unable to express a response in words due to cognitive or physical problems. However, 84% of physicians believed that intensity of pain experienced by patients was inconsistent with physicians’ assessment.

Table 3 shows the perspectives of the physicians interviewed on questions about applying opioid drugs in cancer pain management. A total of 90% of physicians thought that opioid therapy is the first-line approach for the treatment of moderate-to-severe cancer pain.

**Perceptions of patients toward pain and pain treatment**

Perceptions of patients could be acquired from Table 4. Of the 250 patients surveyed, 80.8% expressed that the physician who was primarily responsible for their illness was a cancer specialist. Only 12% of patients surveyed were undertaken by a pain specialist; 73.2% of patients were asked about pain by their physicians at every visit, and 67.2% of patients expressed that a pain scale was used to assess pain intensity. The proportion of pain scale usage by physicians perceived by patients and physicians is shown in Figure S1B.

Table 1 Background information of physicians surveyed (n = 100)

| Parameters                     | Proportion |
|--------------------------------|------------|
| Age (years)                    |            |
| 20–39                          | 42%        |
| ≥40                            | 58%        |
| Gender                         |            |
| Male                           | 50%        |
| Female                         | 50%        |
| Years in clinical practice     |            |
| Median (50%), IQR              | 15, 9.5    |
| 1–5                            | 4%         |
| 6–10                           | 20%        |
| 11–20                          | 51%        |
| 21–30                          | 23%        |
| >30                            | 2%         |
| Work environment               |            |
| Private practice               | –          |
| Teaching hospital              | 32%        |
| Community hospital/government hospital | 62% |
| Comprehensive cancer center    | 6%         |
| Specialization (cancer)        |            |
| Medical oncologist/hemato-oncologist | 98% |
| Surgical oncology              | 2%         |

Abbreviation: IQR, interquartile range.

Table 2 Background information of patients surveyed (n = 250)

| Parameters                                      | Proportion |
|------------------------------------------------|------------|
| Age (years)                                    |            |
| Mean                                           | 60.7       |
| Median, IQR                                    | 62.18      |
| ≤50                                            | 22.8%      |
| 51–65                                          | 36.0%      |
| >65                                            | 41.2%      |
| Gender                                         |            |
| Female                                         | 48.8%      |
| Male                                           | 51.2%      |
| Education completed                            |            |
| Primary/elementary school                      | 47.2%      |
| High school                                    | 39.2%      |
| Tertiary, bachelor’s degree or above            | 13.6%      |
| Current perceived level of pain (BS-11 pain scale score) | | |
| Median, IQR                                    | 6, 3       |
| Mild pain (0–3)                                | 12.0%      |
| Moderate pain (4–6)                            | 38.8%      |
| Severe pain (7–10)                             | 49.2%      |
| Duration of pain (months)                      |            |
| Median, IQR                                    | 6, 9       |
| <3                                             | 19.6%      |
| 3–6                                            | 31.2%      |
| 6–12                                           | 29.6%      |
| >12                                            | 19.6%      |
| Did your physician inform you of the cause of your cancer pain? | | |
| Yes                                            | 94.4%      |
| No                                             | 5.6%       |
| Related to cancer/tumor                        | 80%        |
| Related to chemotherapy/radiotherapy            | 3.0%       |
| Related to both                                | 17.0%      |
| Primary physician responsible for cancer treatment | | |
| Cancer specialist                              | 80.8%      |
| Pain specialist                                | 12.0%      |
| Surgeon and general physician/practitioner     | 7.2%       |

Abbreviation: IQR, interquartile range.
**Table 3** Physicians’ perspectives on cancer pain management

| Survey questions (n = 100) | Proportion |
|---------------------------|------------|
| Education/training        |            |
| Do you feel that your medical school training with regard to cancer pain management was adequate? | 28% |
| Do you feel that your residency training in cancer pain management was adequate? | 17% |
| Do you feel that your medical school training for prescribing opioids (for managing cancer pain) was adequate? | 22% |
| Do you feel that your residency training for prescribing opioids (for managing cancer pain) was adequate? | 20% |
| How much pain-related CME do you receive per year? |            |
| ≤10 hours | 38% |
| >10 hours | 62% |
| Do you believe that guidelines for pain management are important? |            |
| Yes | 97% |
| No | 3% |
| At what level are pain management guidelines most appropriate? |            |
| Hospital/practice specific | 7% |
| National | 53% |
| International | 40% |
| What guidelines do you adhere to? |            |
| International guidelines | 70% |
| NCCN clinical practice guidelines in oncology | 53% |
| WHO 3-step analgesic ladder | 21% |
| EAPC guidelines | 2% |
| Western/European/American guidelines | 2% |
| Are all patients screened for pain on first and subsequent visits? |            |
| Median, IQR | 8, 4.5 |
| Usually “yes” (6 ≤ NRS ≤ 10) | 73% |
| Usually “no” (1 ≤ NRS ≤ 5) | 27% |
| For patients who present with pain, did you routinely assess to quantify pain using pain scale? |            |
| Median, IQR | 7.5, 3.5 |
| Usually “yes” (6 ≤ NRS ≤ 10) | 80% |
| Usually “no” (1 ≤ NRS ≤ 5) | 20% |
| Was intensity of pain experienced by patients inconsistent with physicians’ assessment? |            |
| Median, IQR | 7, 2 |
| Usually “yes” (6 ≤ NRS ≤ 10) | 84% |
| Usually “no” (1 ≤ NRS ≤ 5) | 16% |
| Please mark your agreement with regard to your attitude on opioid usage in pain management |            |
| Opioid therapy is the first-line approach for treatment of moderate-to-severe cancer pain | 90% (8, 3) |
| Regularly scheduled opioid dosing is more effective than as needed dosing for chronic cancer pain | 79% (8, 3.5) |
| If opioid-related adverse effects are significant, an improved balance between analgesia and adverse effects might be achieved by changing to an equivalent dose of an alternative opioid | 87% (8, 3) |
| If side effects persist, consider opioid rotation | 83% (8, 3.5) |

**Notes:** NRS > 5 denotes a response indicating inadequacy or agreement, NRS ≤ 5 denotes a neutral response and NRS < 5 denotes inadequacy or disagreement. The survey results were expressed as a percentage of NRS > 5, the median NRS and the IQR of NRS.

**Abbreviations:** CME, continuing medical education; NCCN, National Comprehensive Cancer Network; WHO, World Health Organization; EAPC, European Association for Palliative Care; IQR, interquartile range; NRS, numerical rating scale.

**Table 4** Patients’ perspectives on screening, assessment and treatment of pain

| Survey questions | Proportion |
|------------------|------------|
| How did you describe physician who is primarily responsible for your illness? (n = 250) |            |
| Cancer specialist | 80.8% |
| Pain specialist | 12.0% |
| Surgeon/general physician/general practitioner | 7.2% |
| What is the frequency of visits to primary physician (cancer)? (n = 250) |            |
| More than once a month | 71.6% |
| Once a month | 19.2% |
| Less than once every 3 months | 9.2% |
| What is the frequency of questioning with regard to pain by physician? (n = 250) |            |
| At every visit | 73.2% |
| At less than half of the visits | 16.4% |
| At more than half of the visits | 7.6% |
| Only occasionally | 2.8% |
| Did the physician use pain scale to assess pain? (n = 250) |            |
| Yes | 67.2% |
| No | 32.8% |
| Are you being treated for pain? (n = 250) |            |
| Yes | 90.0% |
| No | 10.0% |
| What types of treatment did you receive? (n = 240) |            |
| Oral medicine (tablets, syrups) | 84.2% |
| Injectable medicine | 19.6% |
| Transdermal patches | 13.8% |
| Traditional Chinese medicine | 15.0% |
| Interventional pain medication/physical therapy (massage, heat, hydrotherapy)/psychological therapy | 12.1% |
| How many types of treatment did you receive? (n = 240) |            |
| One option | 67.1% |
| More than one option | 32.9% |
| Did your physician change pain medication before? (n = 240) |            |
| Yes | 38.8% |
| No | 52.9% |
| Do not know | 8.3% |
| Did you request to change pain medication? (n = 240) |            |
| Yes | 35.0% |
| No | 65.0% |
| Could you recall the type of pain treatment received? (n = 240) |            |
| Yes | 61.3% |
| No | 38.7% |
| What were you prescribed with? (n = 147) |            |
| Opioids | 83.7% |
| Non-opioid painkillers (includes analgesics, NSAIDs) | 28.6% |
| Have you experienced constipation due to opioid use? (n = 123) |            |
| Yes | 82.9% |
| No | 17.1% |
| Have you taken laxatives as a result of opioid-induced constipation? (n = 123) |            |
| Yes | 70.7% |
| No | 29.3% |
| What types of side effects due to pain medication did you have? (n = 240) |            |
| Nausea/vomiting | 32.5% |
| Sleepiness/drowsiness | 15.4% |
| Dizziness/giddiness | 11.7% |
| Tiredness | 12.1% |

**Abbreviation:** NSAIDs, nonsteroidal anti-inflammatory drugs.
Of the 147 patients who recalled the medication received, 83.7% were administered opioid prescriptions and 28.6% received non-opioid analgesics (including nonsteroidal anti-inflammatory drugs). Of the 123 patients who took opioids, 82.9% experienced constipation due to opioid use and 70.7% had taken laxatives as a result of opioid-induced constipation. Other side effects due to pain medication were prevalent in patients, such as nausea/vomiting, sleepiness/drowsiness, dizziness/giddiness and tiredness (Table 4).

**Outcome and barriers of pain management and impact of pain on patients’ life**

Of the 240 patients who received therapy, 51.7% reported satisfaction with treatment and 43.8% reported that current treatment was inadequate for controlling pain. When unrelieved pain was told to physicians by patients, the corresponding proportion of patients claimed that dose adjustments, the addition of other analgesics, switching of analgesic drugs and referral to another physician were advised by physicians, as shown in Table 5.

Several aspects of daily life that were affected due to pain were reported by patients, as shown in Table 5, such as sleeping pattern, concentration and focus. In addition, 86.8% of patients reported unemployment. Affected performance at work by pain and discontinued work due to pain were common in 13.2% of patients who were employed (Table 5).

In the perspectives of physicians interviewed, barriers to optimize management of cancer pain (especially with regard to opioids) arose from three aspects shown in Figure 2: patients, physicians and regulatory/policy system. The primary barriers included patients’ fear of side effects (58%), patients’ fear of addiction (53%), patients’ reluctance to report pain (43%), physicians’ reluctance to prescribe (29%), physicians’ inadequacy of pain assessment (27%) and excessive management of opioids (47%).

**Discussion**

This study presented the clinical practices of cancer pain management in a cross-sectional survey in mainland China, derived from ACHEON survey in Asia. Despite proactive pain screening, quantitative pain assessment and guideline-based treatment reported by physicians, underestimate of pain intensity and inadequacy of pain control were reported by patients surveyed.

**Pain assessment**

In this survey, 88% of patients reported moderate-to-severe pain. This result confirmed that pain was still prevalent in cancer patients. Pain assessment is the cornerstone to quality pain management. Thus, accurately assessing pain challenged health care workers since no objective measures exist. The intensity of pain was measured by the patient’s self-report. Our data here showed that 84% of the surveyed physicians perceived the inconsistence of pain assessed by clinical physicians and experienced by patients.

On the one hand, this result strengthened the necessity of use of pain scale by physicians. However, our data here showed that 32.8% of patients and 20% of physicians revealed that pain scale was not used when assessing pain. The reason was not explained. About 27% of physicians perceived no adequate pain assessment of clinicians worsened optimal

| Table 5 Outcome of pain management and impact of pain on patients’ life |
|-----------------------------------|------------------|
| Parameters                         | Proportion |
| Please indicate your level of satisfaction with your current treatment (n = 240) |
| Satisfied                          | 51.7%         |
| Neutral                            | 45.0%         |
| Not satisfied                      | 3.3%          |
| Is your current treatment inadequate for controlling your pain? (n = 240) |
| Yes                                | 43.8%         |
| No                                 | 56.2%         |
| How has your doctor responded after being informed that your pain is not being sufficiently treated? (n = 105) |
| Yes                                | 99.0%         |
| No                                 | 1%            |
| What did physician do when he/she was told pain was not uncontrolled? (n = 104) |
| Adjusts the dose of my pain medication | 60.6% |
| Adds another pain medication       | 46.2%         |
| Switches pain medication           | 28.7%         |
| Refers me to another physician    | 4.8%          |
| Does pain affect daily living? (n = 250) |
| Yes                                | 80.8%         |
| No                                 | 19.2%         |
| Aspects of daily life affected? (n = 202) |
| My pain affects my sleeping pattern | 92.6%         |
| My pain affects my concentration and focus | 90.6%         |
| My pain forces me to rely too much on other people | 81.2%          |
| My pain affects my activities of daily living | 93.1%         |
| Overall, my pain does not allow me to have a good QoL | 64.9%         |
| Are you employed? (n = 250) |
| Yes                                | 13.2%         |
| No                                 | 86.8%         |
| My pain impacts my performance at work (n = 33) |
| Agree somewhat/completely         | 87.9%         |
| How many days did you miss for work? (n = 33) |
| <7 days                            | 21.21%        |
| 7–14 days                          | 15.15%        |
| 15–28 days                         | 3.03%         |
| >28 days                           | 60.61%        |

Abbreviation: QoL, quality of life.
palliative and dynamic assessments, and endeavor to follow up on time after hospital discharge.

Training/education on pain management
Opioid drugs are the mainstay of analgesics for moderate-to-severe pain and consequently are the focus for many guidelines. In our survey, 90% of physicians similarly perceived that opioid therapy was the first-line approach for the treatment of moderate-to-severe cancer pain.

As for training/education, although the majority of physicians perceived the inadequacy of medical school/residency training for prescribing opioids (for managing cancer pain), only 38% of physicians surveyed received ≤10 hours of CME training on cancer pain management per year. In addition, 12% of patients reported that their pain was treated through referral to pain specialist. These results suggested the inadequate training in pain management and the lack of pain specialist. A national survey of US medical oncologists showed the importance of opioid to manage pain and suggested prevalent deficits in knowledge about opioids. A survey of physicians in southwest China reported insufficient training in pain control. Another survey of physicians in four tertiary hospitals of China indicated that creating training opportunities for medical staff was necessary to improve cancer pain management practices.

On the use of opioids for cancer pain, many guidelines were developed to assist in the pain management at both national and international levels, such as WHO 3-step analgesic ladder and European Association for Palliative Care (EAPC) guidelines. The undertreated pain was still often
interpreted as a result of lack of adequate clinical guidelines or a failure to properly implement and comply with the available guidelines. Thus, the training content should include pharmacological information on opioid drugs and evidence-based instruction on how to choose and use them.

Optimizing treatment of cancer pain

In our survey, 83.7% of the 147 patients who recalled the medication received were administered opioids prescription; however, 45% or 3.3% of 240 patients perceived that the level of satisfaction with current treatment was neutral or not satisfied. Dissatisfaction mainly attribute to that pain medications have not relieved pain. As a previous study reported, physicians in mainland China failed to take advantage of opioid analgesics to relieve cancer pain. The poor medication adherence or no achievement to the optimal drug dosage could possibly induce pain not well controlled.

Our questionnaire data presented physicians’ perceived barriers to optimize cancer pain management in mainland China. First, physicians surveyed focused on patient-related factor resulting in barriers. In our survey, besides reluctance to report pain, patients’ reluctance to take opioids caused by their concern about addiction and side effects was perceived by 53% and 58% of physicians. The beliefs of patients about using pain medication have an impact on the treatment they received. In some cases, patients were to be persuaded to receive opioid analgesics or even they refused opioids despite unbearable pain. Many patients considered tolerance and physical dependence as equivalent to psychological addiction. Porter and Jick reported the risk of opioid drug addiction as <4 in 10000 (4/11882 cases), indicating that opioid addiction was extremely rare in patients with no history of drug abuse. With the application of controlled-release opioids, around-the-clock medication may effectively mitigate high peak blood concentrations and reduce the risk of addiction. Given opioid-related adverse effects (particularly constipation), the corresponding treatments were recommended during the course of pain medication. Our survey indicated that 70.7% of 123 patients prescribed with opioids had also taken laxatives.

Second, physicians paid attention to clinician-related and system-related factors resulting in barriers. In our survey, besides physicians’ inadequate pain assessment mentioned earlier, 29% of physicians perceived the physicians’ reluctance to prescribe. About 47% of physicians perceived that there was excessive management of opioids by government’s policy. Cherny et al stated that physicians should be able to prescribe opioids according to the individual needs of each patient. However, laws and regulations in many countries interfered with the medical availability of opioids for the relief of pain. Opioid availability continued to be low throughout most of Asia. Compared with Japan, South Korea, Hong Kong, Nepal, Malaysia, Vietnam, and Thailand, mainland China presented more governmental regulatory policies to prescribe opioids, leading to inadequate opioid access for cancer pain relief. These findings were contradictory to those in Western countries. United States presented major increases in opioid analgesic abuse, mainly due to a growing availability of prescription opioids. Thus, the coordination at the governmental level was needed to balance opioid analgesic control and medical use of opioids. In addition, 32% of physicians perceived the lack of pain palliative medical services in mainland China. Just as reported, palliative medicine was in infancy in China and faced many challenges.

Our data were generated by qualitative questionnaires designed to cover a variety of scenarios in clinical practice of cancer pain management, including screening, assessment, general treatment, management of associated symptoms and issues. We acknowledge that some of the data had constraints and limitations, such as patients’ recall bias and physicians’ answers to cater to social expectations. Moreover, complications were not assessed in order to streamline the survey. However, we believe that this survey in mainland China nevertheless provided a good indicator of current clinical practices.

Conclusion

Professional training/education for physicians and pain knowledge spreading for patients are critical to improve management of cancer pain. This will require a strengthening of cancer pain assessment methods and the use of opioid drugs in a rational and standardized manner to further improve the efficacy of cancer pain control and QoL for patients with cancer.

Acknowledgments

This survey was sponsored by Mundipharma Pte Ltd, Singapore. Mundipharma was the sponsor of the research, participated in the development of the survey protocol and funding of survey conduct, data analysis and medical writing services. The author and the sponsor thank The Research Partnership Healthcare Asia Pte Ltd for survey conduct and data analysis and Beijing Preintell Biomed Co., Ltd for medical writing assistance, funded by Mundipharma (China) Pharmaceutical Co., Ltd. A special thanks to all physicians and patients for their participation in the survey.
Disclosure
The author reports no conflicts of interest in this work.

References
1. Johnson JR, Lossignol D, Burnett-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46(2):207–218.
2. Goudas LC, Bloch R, Gialelei-Goudas M, Lau J, Carr DB. The epidemiology of cancer pain. Cancer Invest. 2005;23(2):182–190.
3. van den Beucken-van Everdingen M, De Rijke J, Kessels A, Schouten H, Van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–1449.
4. van den Beucken-van MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain. 2007;132(3):312–320.
5. Deng D, Fu L, Zhao YX, et al. The relationship between cancer pain and quality of life in patients newly admitted to Wuhan Hospice Center of China. Am J Hosp Palliat Care. 2012;29(1):53–59.
6. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analogics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–e68.
7. Ferrell BR. The impact of pain on quality of life. A decade of research. Nurs Clin North Am. 1995;30(4):609–624.
8. Yu S, Wang XS, Cheng Y, Yang J, Cleeland CS. Special aspects of cancer pain management in a Chinese general hospital. Eur J Pain. 2001;5(suppl A):15–20.
9. Ding Y, Yang P, Sun L-Q, Lu Y-H, Zhang L. Pain management among hospitalized cancer patients: a survey in 30 hospitals in Beijing. Chin J Nurs. 2011;3:26.
10. Oldemenger WH, Smith PAS, van Dooren S, Stoter G, van der Rijt CC. A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal. Eur J Cancer. 2009;45(8):1370–1380.
11. Sun VC-Y, Borneman T, Ferrell B, Piper B, Koczywas M, Choi K. Overcoming barriers to cancer pain management: an institutional change model. J Pain Symptom Manage. 2007;34(4):359–369.
12. Kwon JH. Overcoming barriers in cancer pain management. J Clin Oncol. 2014;32(16):1727–1733.
13. Mercadante S, Porzio G, Ferrera P, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008;12(8):1040–1046.
14. Jacobsen R, Moldrup C, Christrup L, Sjøgren P. Patient-related barriers to cancer pain management: a systematic exploratory review. Scand J Caring Sci. 2009;23(1):190–208.
15. Burton AW, Hamid B. Current challenges in cancer pain management: does the WHO ladder approach still have relevance? Expert Rev Anti-cancer Ther. 2007;7(11):1501–1502.
16. Kim YC, Ahn JS, Calimag MMP, et al. Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries. Cancer Med. 2015;4(8):1196–1204.
17. Fink R. Pain assessment: the cornerstone to optimal pain management. Paper presented at: Baylor University Medical Center. Proceedings; 2000.
18. Green CR, Hart-Johnson T. The adequacy of chronic pain management prior to presenting at a tertiary care pain center: the role of patient socio-demographic characteristics. J Pain. 2010;11(8):746–754.
19. Herr K, Coyne PJ, Key T, et al; American Society for Pain Management Nursing. Pain assessment in the nonverbal patient: position statement with clinical practice recommendations. Pain Manage Nurs. 2006;7(2):44–52.
20. Hjermstad MJ, Fayers PM, Haugen DE, et al; European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011;41(6):1073–1093.
21. Im EO, Liu Y, Kim YH, Chee W. Asian American cancer patients’ pain experience. Cancer Nurs. 2008;31(3):E17–E23.
22. Syrjala KL, Abrams JR, Polissar NL, et al. Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain. 2008;135(1):175–186.
23. Jacobsen R, Sjøgren P, Moldrup C, Christrup L. Physician-related barriers to cancer pain management with opioid analogics: a systematic review. J Opioid Manag. 2007;3(4):207–214.
24. Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists’ attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011;29(6):4769–4775.
25. Liao Z, Hao J, Guo Y, Reyes-Gibby C, Guo H. Assessment of cancer pain management knowledge in southwest China: a survey of 259 physicians from small city and county hospitals. J Palliat Med. 2013;16(6):692–695.
26. Yanjun S, Changli W, Ling W, et al. A survey on physician knowledge and attitudes towards clinical use of morphine for cancer pain treatment in China. Support Care Cancer. 2010;18(11):1455–1460.
27. Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420–1433.
28. Pigni A, Brunelli C, Gibbins J, et al. Content development for EUROPEAN GUIDELINES on the use of opioids for cancer pain: a systematic review and Expert Consensus Study. Minerva Anestesiol. 2010;76(10):833.
29. Li J, Davis MP, Gamier P. Palliative medicine: barriers and developments in mainland China. Eur J Pain. 2011;13(4):290–294.
30. Cohen E, Botti M, Hanna B, Leach S, Boyd S, Robbins J. Pain beliefs and pain management of oncology patients. Cancer Nurs. 2008;31(2):E1–E8.
31. Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 1980;302(2):123.
32. Cherry N, Cleary J, Scholten W, Radbruch L, Torode J. The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: introduction and methodology. Ann Oncol. 2013;24(suppl 11):ix17–ix13.
33. Manjiani D, Paul DB, Kunnumpurath S, Kaye AD, Vadivelu N. Availability and utilization of opioids for pain management: global issues. Ochsner J. 2014;14(2):208–215.
34. Cleary J, Radbruch L, Torode J, Cherry N. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Asia: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol. 2013;24(suppl 11):ix24–ix32.
35. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006;81(2):103–107.
Supplementary material

Figure S1 Practices of pain assessment.
Notes: (A) Pain assessment tools employed by physicians (n = 100). Multifaceted approaches included direct observation, description by family members or caregivers. (B) Frequency of usage of a pain scale to assess cancer pain, as reported by patients and physicians.
Abbreviations: FACES, facial expression scale; CNPI, Checklist of Nonverbal Pain Indicators; ADD, Assessment of Discomfort in Dementia Protocol; PAINAD, Pain Assessment in Advanced Dementia Scale.